Acorda Therapeutics Cdt Stock
Your prediction
Pros and Cons of Acorda Therapeutics Cdt in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acorda Therapeutics Cdt vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Acorda Therapeutics Cdt | - | - | - | - | - | - | - |
| Heron Therapeutics Inc. | -0.410% | 10.879% | -0.581% | -54.196% | -30.925% | -70.630% | -94.480% |
| Evolus Inc | -0.550% | 3.399% | -16.590% | -59.326% | -33.578% | -51.733% | -63.061% |
| Sangamo Therapeutics Inc. | -0.810% | -2.426% | -34.637% | -67.260% | -37.907% | -85.570% | -97.764% |
Comments
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat